Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

In recent decades, the advent of immune-based therapies, most notably Chimeric antigen
receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of …

Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …

Cell-based therapies are emerging as effective agents against cancer and other diseases.
As autonomous “living drugs,” these therapies lack precise control. Chimeric antigen …

The emergence of various novel therapies over the last decade has changed the therapeutic
landscape for multiple myeloma. While the clinical outcomes have improved significantly …

Chimeric antigen receptor (CAR)-T cell therapy represents a landmark advance in
personalized cancer treatment. CAR-T strategy generally engineers T cells from a specific …

Chimeric antigen receptors (CAR) are fusion proteins containing an antigen-recognition
domain coupled to a T-cell activation domain (eg, CD3ζ [CD247]) and to a costimulatory …

Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy
against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse …

A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …

Over the past decades, immunotherapy has demonstrated a prominent clinical efficacy in a
wide variety of human tumors. For many years, apoptosis has been considered a non …